• Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

    8 monthes ago - By News Medical

    Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.
    Read more ...